Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0E0FY
|
||||
Former ID |
DIB013182
|
||||
Drug Name |
CTL-102-GDEPT
|
||||
Synonyms |
CTL-102; NTR-GDEPT; GDEPT (CTL-102), ML Laboratories; Gene directed chemotherapy (CTL-102), ML Laboratories; Ad-NTR + CB-1954 GDEPT, ML Labs; Human adenovirus (hAdV5) GDEPT (E coli nitroreductase (NTR)/CB-1954, aseptic prosthetic implant loosening), Broadvector
|
||||
Indication | Head and neck cancer [ICD9: 140-149, 140-229; ICD10:C07-C14, C32-C33] | Discontinued in Phase 2 | [546958] | ||
Company |
Cobra Biomanufacturing plc
|
||||
Target and Pathway | |||||
Target(s) | Aldose reductase | Target Info | Modulator | [549941] | |
NetPath Pathway | IL1 Signaling Pathway | ||||
TGF_beta_Receptor Signaling Pathway | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.